CoChat

Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial

Open access
Perkovic, Vlado, Koitka-Weber, Audrey, Cooper, Mark E, Schernthaner, Guntram, Pfarr, Egon, Woerle, Hans J, von Eynatten, Maximilian, Wanner, Christoph · 2020 · Nephrology Dialysis Transplantation
Cited by 31

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Background: Doubling of serum creatinine [equivalent to 57% reduction in estimated glomerular filtration rate (eGFR)] is an established surrogate for end-stage kidney disease (ESKD); however, this endpoint necessitates lengthy follow-up and large sample sizes in clinical trials. We explored whether alternative eGFR decline thresholds provide more feasible surrogate kidney endpoints. Methods: The study involved post hoc analysis of the EMPA-REG OUTCOME® trial. Adults with type 2 diabetes, high cardiovascular risk and eGFR ≥30 mL/min/1.73 m2 were assigned empagliflozin 10 mg or 25 mg (n = 4687) or placebo (n = 2333), on top of standard of care. We assessed composite endpoints incorporating different eGFR decline thresholds (≥30, ≥40, ≥50 or ≥57%) combined with initiation of renal replacement therapy (RRT) or renal death. This trial is registered with ClinicalTrials.gov (NCT01131676). Results: Empagliflozin versus placebo significantly lowered the risk of decline in eGFR for each threshold listed above, combined with initiation of RRT or renal death, ranging from a hazard ratio (HR) of 0.81 [95% confidence interval (CI) 0.72–0.91] for endpoints based on 30% eGFR decline to an HR of 0.37 (0.23–0.61) for endpoints based on 57% eGFR decline. Lower thresholds (e.g. 30%) were associated with higher event rates but weaker treatment effects. The time to the 95% CI of the HR falling to <1.0 decreased with increasing eGFR threshold. Conclusions: The composite of 40% decline in eGFR, ESKD or renal death appears to provide reliable results similar to the traditional 57% decline in eGFR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ndt/gfz179

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 31

Metadata

Authors
Perkovic, V., Koitka-Weber, A., Cooper, M. E., Schernthaner, G., Pfarr, E., Woerle, H. J., von Eynatten, M., & Wanner, C.
Venue
Nephrology Dialysis Transplantation
Published
2019-09-08
Volume
35
Issue
12
Pages
2103-2111
ISSN
  • 0931-0509 (ISSN-L)
  • 1460-2385
OpenAlex
W2972688698
Cited by
31
References
5
FWCI
2.86
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. https://app.cochat.ai/papers/10.1093/ndt/gfz179
The paper
Perkovic, V., Koitka-Weber, A., Cooper, M. E., Schernthaner, G., Pfarr, E., Woerle, H. J., von Eynatten, M., & Wanner, C. (2020). Choice of endpoint in kidney outcome trials: considerations from the EMPA-REG OUTCOME® trial. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfz179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.